Cargando…

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study

BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown promising antitumor activity against a range of advanced cancers. However, evidence is lacking as to whether this combination therapy could benefit thymic epithelial tumors (TETs). We aimed to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Jing, Si, Jinfei, Hao, Yue, Wei, Jingwen, Wang, Wenxian, Guan, Yelan, Xu, Chunwei, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080305/ https://www.ncbi.nlm.nih.gov/pubmed/37033336 http://dx.doi.org/10.21037/tcr-22-2192

Ejemplares similares

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
por: Guan, Yelan, et al.
Publicado: (2023)

Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
por: Hao, Yue, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
por: Guan, Yelan, et al.
Publicado: (2023)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
por: Wei, Jingwen, et al.
Publicado: (2022)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors
por: Owen, Dwight H., et al.
Publicado: (2019)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Establishment of multi-center database on thymic epithelial tumors (TETs) and current situation in Korea
por: Kim, Dong Kwan
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
por: Hao, Yue, et al.
Publicado: (2022)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Immune checkpoints in thymic epithelial tumors: challenges and opportunities
por: Girard, Nicolas
Publicado: (2019)

Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020)

Rare frequency of gene variation and survival analysis in thymic epithelial tumors
por: Song, Zhengbo, et al.
Publicado: (2016)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
por: Shah, Neil J., et al.
Publicado: (2019)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort
por: Guan, Yelan, et al.
Publicado: (2023)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Nomogram based on TNM stage to predict the prognosis of thymic epithelial tumors (TETs) patients undergoing extended thymectomy
por: Li, Yanzhi, et al.
Publicado: (2023)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
por: Shi, Congqi, et al.
Publicado: (2022)

Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level
por: Qian, Xinyu, et al.
Publicado: (2016)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
por: Zhao, Chen, et al.
Publicado: (2019)

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
por: Safi, Mohammed, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
por: Jiang, Joanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ldi2r93jrcrclrlmbd8qonq7j0